Tumor Necrosis Factor Receptor Blocking Activity

Name
Tumor Necrosis Factor Receptor Blocking Activity
Accession Number
DBCAT004095
Description

Not Available

Drugs
DrugDrug Description
GolimumabA TNF╬▒ inhibitor used in the symptomatic treatment of various active inflammatory disorders, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.
Certolizumab pegolA tumor necrosis factor (TNF) blocker used to treat a variety of autoimmune and autoinflammatory conditions like Crohn's disease, rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, and plaque psoriasis.
AdalimumabA monoclonal anti-tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis.
InfliximabA monoclonal anti tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis.
Drugs & Drug Targets
DrugTargetType
GolimumabTumor necrosis factortarget
Certolizumab pegolTumor necrosis factortarget
Certolizumab pegolAlcohol dehydrogenase [NADP(+)]enzyme
AdalimumabTumor necrosis factortarget
InfliximabTumor necrosis factortarget